Evidence reviews - September 2025
The following document contains the evidence that was used to develop the 2025 recommendations:
- Diagnostic accuracy of lung ultrasound compared to chest X-ray for diagnosing pneumonia
- Clinical and cost-effectiveness of care outside of the acute hospital inpatient setting for people with community-acquired pneumonia who would otherwise be admitted to hospital
- Microbiological tests at presentation in secondary care to inform treatment decisions in people with suspected community- or hospital-acquired pneumonia
- Short courses of antibiotics compared to longer courses of antibiotics for babies, children and young people with community-acquired pneumonia
- Corticosteroids as an adjunct to antibiotics in adults with community- or hospital-acquired pneumonia
- Non-invasive respiratory support for people hospitalised with pneumonia
- Information for parents and carers of babies, children and young people about expected symptoms and duration of symptoms following treatment for CAP or HAP
- Clinical and cost effectiveness of monitoring biomarkers to determine when to de-escalate or change place of care for people in hospital with CAP or HAP
- Effectiveness and cost-effectiveness of routine chest X-rays at 6-weeks post discharge for identifying underlying disease in people hospitalised with pneumonia
- Pneumonia outcome prediction tools for babies, children and young people presenting to primary care
- Prognostic accuracy of NEWS2 and PEWS in people with community-acquired pneumonia
Other supporting evidence
This page was last updated: